Merck to return Kuvan drug rights to BioMarin Pharmaceutical
In 2005, Merck bought the rights to Kuvan and Peg-Pal, another PKU treatment, outside the US and Japan. BioMarin will pay Merck €340m for Kuvan and about €185m
QIAGEN’s Digital Insights bioinformatics division is set to integrate NVIDIA’s accelerated computing and the BioNeMo platform to enhance AI-driven drug discovery.
The document provides guidance for the conduct of robust analyses to facilitate and speed up the development of new antibiotics, in particular those targeting multi-drug resistant bacteria. Comments
APP-111 showed efficacy in preclinical studies against hormone sensitive, castration resistant, as well as taxane resistant prostate cancer. In preclinical studies, the drug appeared to have less peripheral